GlassScriptPhysician profile
Nathan Morgan
NPI 1215364674
$43,881.05
in general payments reported to CMS, 2019-2025
31 companies · $8,791 in 2025
The $8,791 reported for 2025 was more than what 99% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,917 · 2022: $5,482 · 2023: $15K · 2024: $12K · 2025: $8,791.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $18K · Food and Beverage: $14K · Travel and Lodging: $2,479 · Education: $805 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $720.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $18,455.40 |
| Food and Beverage | $14,023.70 |
| Travel and Lodging | $2,478.72 |
| Education | $804.83 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $720.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arcutis Biotherapeutics, INC. | $10,765.28 | 2023-2025 | Zoryve |
| Ucb, INC. | $6,405.25 | 2021-2025 | Bimzelx, Cimzia |
| Abbvie INC. | $5,227.46 | 2022-2025 | |
| Janssen Biotech, INC. | $4,373.72 | 2021-2025 | Tremfya |
| Dermavant Sciences, INC. | $2,665.74 | 2022-2024 | Vtama |
| Leo Pharma INC. | $2,605.83 | 2022-2025 | Adbry, Anzupgo |
| Pfizer INC. | $1,721.35 | 2021-2025 | |
| Galderma Laboratories, L.P. | $1,273.83 | 2021-2025 | Aklief, Epsolay, Oracea |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $1,092.32 | 2021-2024 | Siliq, Targretin, Cabtreo |
| Sun Pharmaceutical Industries INC. | $952.26 | 2021-2025 | Ilumya, Absorica Ld, Winlevi |
| Genzyme Corporation | $938.10 | 2021-2025 | |
| Epi Health, LLC | $890.82 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $804.38 | 2022-2025 | Sotyktu |
| Regeneron Healthcare Solutions, INC. | $678.10 | 2021-2025 | Dupixent, Libtayo |
| Novartis Pharmaceuticals Corporation | $624.09 | 2022-2025 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Journey Medical Corporation | $483.93 | 2021-2024 | |
| Lilly USA, LLC | $382.81 | 2022-2025 | Taltz, Ebglyss, Olumiant |
| Amgen INC. | $368.26 | 2021-2025 | Otezla, Enbrel, Otezla |
| Biofrontera INC. | $268.12 | 2021-2025 | Xepi, Bf-Rhodoled, Ameluz |
| Organogenesis INC. | $232.25 | 2021-2025 | Puraply Wound Matrix |
| Incyte Corporation | $214.40 | 2021-2025 | Opzelura |
| Organon LLC | $210.49 | 2025 | Vtama |
| Janssen Scientific Affairs, LLC | $181.20 | 2023-2024 | Tremfya |
| Boehringer Ingelheim Pharmaceuticals, INC. | $170.95 | 2022-2025 | Cyltezo, Spevigo |
| Vyne Pharmaceuticals INC. | $129.70 | 2021 | |
| Helsinn Therapeutics (U.S.), INC. | $100.06 | 2022-2025 | Valchlor |
| Botanix Sb INC | $42.36 | 2025 | Sofdra |
| Almirall LLC | $27.71 | 2022-2025 | Seysara |
| Verrica Pharmaceuticals INC. | $24.68 | 2023 | Ycanth |
| Mimedx Group, INC. | $13.67 | 2024 | |
| Biodermis LLC | $11.93 | 2025 | Pro-Sil, Epi-Derm, Biocorneum |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nathan Morgan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.